Deutsche Bank AG Purchases Shares of 45,144 Azenta, Inc. $AZTA

Key Points

• Deutsche Bank AG initiated a stake in Azenta during the second quarter, purchasing 45,144 shares valued at approximately $1.15 million, or 0.10% of the company.
• Institutional investors and hedge funds own 99.08% of Azenta, with several firms increasing their positions recently.
• Azenta beat quarterly expectations, reporting $0.16 in earnings per share and $161.18 million in revenue, while analysts maintain a consensus “Hold” rating and a $41.20 price target.

Deutsche Bank AG purchased a new stake in Azenta, Inc. (NASDAQ:AZTA - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 45,144 shares of the company's stock, valued at approximately $1,152,000. Deutsche Bank AG owned 0.10% of Azenta as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Caitong International Asset Management Co. Ltd raised its stake in shares of Azenta by 2,067.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company's stock valued at $27,000 after purchasing an additional 765 shares in the last quarter. State of Wyoming bought a new stake in Azenta in the 1st quarter valued at $38,000. Osaic Holdings Inc. raised its stake in shares of Azenta by 44.9% in the 2nd quarter. Osaic Holdings Inc. now owns 1,242 shares of the company's stock valued at $39,000 after buying an additional 385 shares in the last quarter. Rockefeller Capital Management L.P. lifted its holdings in shares of Azenta by 98.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,392 shares of the company's stock worth $46,000 after acquiring an additional 689 shares during the period. Finally, KBC Group NV boosted its position in shares of Azenta by 102.2% during the 1st quarter. KBC Group NV now owns 2,449 shares of the company's stock valued at $52,000 after acquiring an additional 1,238 shares in the last quarter. 99.08% of the stock is currently owned by institutional investors and hedge funds.

Azenta Price Performance

Shares of AZTA stock opened at $32.95 on Monday. Azenta, Inc. has a 12-month low of $15.93 and a 12-month high of $41.73. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of -11.94 and a beta of 1.37. The firm has a fifty day moving average of $28.93 and a 200-day moving average of $25.16.

Azenta (NASDAQ:AZTA - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.11 by $0.05. The firm had revenue of $161.18 million for the quarter, compared to the consensus estimate of $149.31 million. Azenta had a negative net margin of 20.63% and a positive return on equity of 1.18%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Weiss Ratings raised Azenta from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday. Needham & Company LLC increased their price objective on Azenta from $33.00 to $37.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Azenta presently has an average rating of "Hold" and a consensus target price of $41.20.

Azenta Company Profile

Azenta, Inc NASDAQ: AZTA is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta's Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.

Want to see what other hedge funds are holding AZTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Azenta, Inc. (NASDAQ:AZTA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source